Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/ II Study of Fragmented Autoantigen Stimulated T-cell-immunotherapy Combined with Radiotherapy (FAST-CR)

NCT06756295 is registered in ClinicalTrials.gov with Fengming Kong as lead sponsor.

NCT NCT06756295
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06756295 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/ II Study of Fragmented Autoantigen Stimulated T-cell-immunotherapy Combined with Radiotherapy (FAST-CR)
Lead sponsor
Fengming Kong
Phase
Phase 1
Overall status
Not yet recruiting
Start date
March 25, 2025
Completion date
March 1, 2028
Enrollment
154 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, colorectal cancer, lung cancer, melanoma